background: bleeding events in hemophilic patients with inhibitors are managed by bypassing agents. currently available agents in iran are recombinant activated factor vii (rfviia; aryogen, aryoseven) and feiba (factor eight inhibitor bypassing agent). no standardized and accurate assay is currently available for monitoring the effectiveness of bypassing agents. we suggested that history of the...

bypassing agents are the most commonly used medicines for the treatment of hemophilia patients with inhibitors. the aim of this study is to identify the cost components of management of bleeding vents in hemophilia patients with inhibitors in iran. this study is a cross-sectional study using a bottom-up approach to determine the cost components of treatment of hemophilia patients with inhibitor...

conclusions treatment strategies in acquired hemophilia are based on two major objectives. during the acute stage, effective control of bleeding is critical. the ultimate therapeutic goal during the subacute phase is the elimination of the inhibitors targeting factor viii. here, we present this case and will review current literature regarding therapeutic approaches to this rare condition in th...

BACKGROUND Inhibitory antibodies to factor VIII (FVIII) or IX (FIX) are important issues when managing patients with hemophilia A or B. Advances in bypassing agents such as recombinant activated FVII (rFVIIa) and activated prothrombin complex concentrates (APCC) have enabled the aggressive management of hemophilia with inhibitors during emergency or elective surgery. This study provides an upda...

Bypassing agents are the mainstay of treatment for patients with hemophilia with high-titer inhibitors. Whereas the availability of these agents has greatly advanced the management of bleeding episodes in this population, timely administration of bypassing agents continues to be hampered by a number of practical limitations, including the need for refrigerated storage of the agent and its recon...

The development of alloantibodies neutralising therapeutically administered factor (F) VIII/IX (inhibitors) is currently the most severe complication of the treatment of haemophilia. When persistent and at a high titre, inhibitors preclude the standard replacement treatment with FVIII/FIX concentrates, making patients' management challenging. Indeed, the efficacy of bypassing agents, i.e., acti...

Sequential bypassing agents may be a safe and effective treatment during major orthopedic surgery in hemophilia patients with inhibitors.

Positive phase III results for Roche’s emicizumab in haemophilia A published in The New England Journal of Medicine ● HAVEN 1 showed emicizumab reduced bleed rate by 87% compared with on-demand bypassing agents ● All 12 secondary endpoints in HAVEN 1 were positive, including an intra-patient comparison that showed emicizumab reduced bleed rate by 79% compared to prior prophylactic bypassing age...